Bispecific antibodies (BsAbs), particularly blinatumomab—a CD19 × CD3 bispecific T-cell engager (BiTE)—have significantly advanced the treatment paradigm for relapsed or refractory (R/R) ALL. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.